These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 17207146)

  • 1. Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1-4 in Mozambique.
    Macete E; Aponte JJ; Guinovart C; Sacarlal J; Ofori-Anyinam O; Mandomando I; Espasa M; Bevilacqua C; Leach A; Dubois MC; Heppner DG; Tello L; Milman J; Cohen J; Dubovsky F; Tornieporth N; Thompson R; Alonso PL
    Trop Med Int Health; 2007 Jan; 12(1):37-46. PubMed ID: 17207146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children.
    Bojang KA; Olodude F; Pinder M; Ofori-Anyinam O; Vigneron L; Fitzpatrick S; Njie F; Kassanga A; Leach A; Milman J; Rabinovich R; McAdam KP; Kester KE; Heppner DG; Cohen JD; Tornieporth N; Milligan PJ
    Vaccine; 2005 Jul; 23(32):4148-57. PubMed ID: 15964483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial.
    Sacarlal J; Aponte JJ; Aide P; Mandomando I; Bassat Q; Guinovart C; Leach A; Milman J; Macete E; Espasa M; Ofori-Anyinam O; Thonnard J; Corachan S; Dubois MC; Lievens M; Dubovsky F; Ballou WR; Cohen J; Alonso PL
    Vaccine; 2008 Jan; 26(2):174-84. PubMed ID: 18069097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial.
    Macete EV; Sacarlal J; Aponte JJ; Leach A; Navia MM; Milman J; Guinovart C; Mandomando I; López-Púa Y; Lievens M; Owusu-Ofori A; Dubois MC; Cahill CP; Koutsoukos M; Sillman M; Thompson R; Dubovsky F; Ballou WR; Cohen J; Alonso PL
    Trials; 2007 Mar; 8():11. PubMed ID: 17386091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.
    Kester KE; Cummings JF; Ofori-Anyinam O; Ockenhouse CF; Krzych U; Moris P; Schwenk R; Nielsen RA; Debebe Z; Pinelis E; Juompan L; Williams J; Dowler M; Stewart VA; Wirtz RA; Dubois MC; Lievens M; Cohen J; Ballou WR; Heppner DG;
    J Infect Dis; 2009 Aug; 200(3):337-46. PubMed ID: 19569965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya.
    Stoute JA; Heppner DG; Mason CJ; Siangla J; Opollo MO; Kester KE; Vigneron L; Voss G; Walter MJ; Tornieporth N; Cohen JD; Ballou WR
    Am J Trop Med Hyg; 2006 Jul; 75(1):166-70. PubMed ID: 16837726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants.
    Abdulla S; Oberholzer R; Juma O; Kubhoja S; Machera F; Membi C; Omari S; Urassa A; Mshinda H; Jumanne A; Salim N; Shomari M; Aebi T; Schellenberg DM; Carter T; Villafana T; Demoitié MA; Dubois MC; Leach A; Lievens M; Vekemans J; Cohen J; Ballou WR; Tanner M
    N Engl J Med; 2008 Dec; 359(24):2533-44. PubMed ID: 19064623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of rts,s+trap malaria vaccine, formulated in the as02a adjuvant system, in infant rhesus monkeys.
    Walsh DS; Pichyangkul S; Gettayacamin M; Tongtawe P; Siegrist CA; Hansukjariya P; Kester KE; Holland CA; Voss G; Cohen J; Stewart AV; Miller RS; Ballou WR; Heppner DG
    Am J Trop Med Hyg; 2004 May; 70(5):499-509. PubMed ID: 15155981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial.
    Aide P; Dobaño C; Sacarlal J; Aponte JJ; Mandomando I; Guinovart C; Bassat Q; Renom M; Puyol L; Macete E; Herreros E; Leach A; Dubois MC; Demoitie MA; Lievens M; Vekemans J; Loucq C; Ballou WR; Cohen J; Alonso PL
    Vaccine; 2011 Aug; 29(35):6059-67. PubMed ID: 21443960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children.
    Sacarlal J; Aide P; Aponte JJ; Renom M; Leach A; Mandomando I; Lievens M; Bassat Q; Lafuente S; Macete E; Vekemans J; Guinovart C; Sigaúque B; Sillman M; Milman J; Dubois MC; Demoitié MA; Thonnard J; Menéndez C; Ballou WR; Cohen J; Alonso PL
    J Infect Dis; 2009 Aug; 200(3):329-36. PubMed ID: 19569964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial.
    Aponte JJ; Aide P; Renom M; Mandomando I; Bassat Q; Sacarlal J; Manaca MN; Lafuente S; Barbosa A; Leach A; Lievens M; Vekemans J; Sigauque B; Dubois MC; Demoitié MA; Sillman M; Savarese B; McNeil JG; Macete E; Ballou WR; Cohen J; Alonso PL
    Lancet; 2007 Nov; 370(9598):1543-51. PubMed ID: 17949807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.
    Walsh DS; Gettayacamin M; Leitner WW; Lyon JA; Stewart VA; Marit G; Pichyangkul S; Gosi P; Tongtawe P; Kester KE; Holland CA; Kolodny N; Cohen J; Voss G; Ballou WR; Heppner DG
    Vaccine; 2006 May; 24(19):4167-78. PubMed ID: 16574282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial.
    Alonso PL; Sacarlal J; Aponte JJ; Leach A; Macete E; Milman J; Mandomando I; Spiessens B; Guinovart C; Espasa M; Bassat Q; Aide P; Ofori-Anyinam O; Navia MM; Corachan S; Ceuppens M; Dubois MC; Demoitié MA; Dubovsky F; Menéndez C; Tornieporth N; Ballou WR; Thompson R; Cohen J
    Lancet; 2004 Oct 16-22; 364(9443):1411-20. PubMed ID: 15488216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.
    Stewart VA; McGrath SM; Walsh DS; Davis S; Hess AS; Ware LA; Kester KE; Cummings JF; Burge JR; Voss G; Delchambre M; Garçon N; Tang DB; Cohen JD; Heppner DG
    Vaccine; 2006 Oct; 24(42-43):6483-92. PubMed ID: 16904798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya.
    Stoute JA; Gombe J; Withers MR; Siangla J; McKinney D; Onyango M; Cummings JF; Milman J; Tucker K; Soisson L; Stewart VA; Lyon JA; Angov E; Leach A; Cohen J; Kester KE; Ockenhouse CF; Holland CA; Diggs CL; Wittes J; Heppner DG;
    Vaccine; 2007 Jan; 25(1):176-84. PubMed ID: 16388879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
    Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
    Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
    Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
    Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RTS,S/AS02A for malaria.
    Bojang KA
    Expert Rev Vaccines; 2006 Oct; 5(5):611-5. PubMed ID: 17181435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.
    Heppner DG; Kester KE; Ockenhouse CF; Tornieporth N; Ofori O; Lyon JA; Stewart VA; Dubois P; Lanar DE; Krzych U; Moris P; Angov E; Cummings JF; Leach A; Hall BT; Dutta S; Schwenk R; Hillier C; Barbosa A; Ware LA; Nair L; Darko CA; Withers MR; Ogutu B; Polhemus ME; Fukuda M; Pichyangkul S; Gettyacamin M; Diggs C; Soisson L; Milman J; Dubois MC; Garçon N; Tucker K; Wittes J; Plowe CV; Thera MA; Duombo OK; Pau MG; Goudsmit J; Ballou WR; Cohen J
    Vaccine; 2005 Mar; 23(17-18):2243-50. PubMed ID: 15755604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.
    Stoute JA; Slaoui M; Heppner DG; Momin P; Kester KE; Desmons P; Wellde BT; Garçon N; Krzych U; Marchand M
    N Engl J Med; 1997 Jan; 336(2):86-91. PubMed ID: 8988885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.